(Arg)9-SH2 superbinder: a novel promising anticancer therapy to melanoma by blocking phosphotyrosine signaling

Ultra-deep tyrosine phosphoproteomics enabled by a phosphotyrosine superbinder

(2016) Yangyang Bian et al.   Nature Chemical Biology

Molecular Targeted Therapy Approaches for BRAF Wild-Type Melanoma

(2016) Romany A. N. Johnpulle et al.   Current Oncology Reports

Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation

(2015) Tea Pemovska et al.   NATURE

Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

BRAF Inhibitor Resistance Mechanisms in Metastatic Melanoma: Spectrum and Clinical Impact

(2014) H. Rizos et al.   CLINICAL CANCER RESEARCH

Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma

(2014) Georgina V. Long et al.   NEW ENGLAND JOURNAL OF MEDICINE

Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma

(2014) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

FAK competes for Src to promote migration against invasion in melanoma cells

(2014) K Kolli-Bouhafs et al.   Cell Death & Disease

Tyrosine Kinase Inhibitors: Views of Selectivity, Sensitivity, and Clinical Performance

(2012) Alexander Levitzki   Annual Review of Pharmacology and Toxicology

Role of Tyrosine Phosphatase Inhibitors in Cancer Treatment with Emphasis on SH2 Domain-Containing Tyrosine Phosphatases (SHPs)

(2012) Mahban Irandoust et al.   Anti-Cancer Agents in Medicinal Chemistry

JAK/STAT autocontrol of ligand-producing cell number through apoptosis

(2012) A. Borensztejn et al.   DEVELOPMENT

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

(2012) Axel Hauschild et al.   LANCET

Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer

(2012) Christopher E Barbieri et al.   NATURE GENETICS

Superbinder SH2 Domains Act as Antagonists of Cell Signaling

(2012) T. Kaneko et al.   Science Signaling

Melanoma whole-exome sequencing identifies V600E B-RAF amplification-mediated acquired B-RAF inhibitor resistance

(2012) Hubing Shi et al.   Nature Communications

Receptor Tyrosine Kinases and Targeted Cancer Therapeutics

(2011) Kenji Takeuchi et al.   BIOLOGICAL & PHARMACEUTICAL BULLETIN

A Cell-permeable Fusion Protein for the Mineralization of Human Dental Pulp Stem Cells

(2011) J.S. Suh et al.   JOURNAL OF DENTAL RESEARCH

Selected reaction monitoring mass spectrometry reveals the dynamics of signaling through the GRB2 adaptor

(2011) Nicolas Bisson et al.   NATURE BIOTECHNOLOGY

The 4G10, pY20 and p-TYR-100 antibody specificity: profiling by peptide microarrays

(2011) Michele Tinti et al.   New Biotechnology

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

(2011) Paul B. Chapman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phosphotyrosine Signaling: Evolving a New Cellular Communication System

(2010) Wendell A. Lim et al.   CELL

ErbB family receptor inhibitors as therapeutic agents in breast cancer: Current status and future clinical perspective

(2010) Ruchi Saxena et al.   MEDICINAL RESEARCH REVIEWS

The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner

(2010) E. W. Joseph et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

ErbB receptors and signaling pathways in cancer

(2009) Nancy E Hynes et al.   CURRENT OPINION IN CELL BIOLOGY

Live-cell analysis of cell penetration ability and toxicity of oligo-arginines

(2007) Gisela Tünnemann et al.   JOURNAL OF PEPTIDE SCIENCE